Matthew T. Wiley - 30 Jun 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Reporting relationship: Chief Commercial Officer
Issuer ticker: VYNE
Reported as of: 30 Jun 2021
Net transaction value: -$18,080
SEC form: 4
Accepted by SEC: 02 Jul 2021, 16:36:53 UTC
Next SEC filing: 19 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Mutya Harsch, attorney-in-fact for Matthew Wiley

Key filing fact

Matthew T. Wiley filed Form 4 for VYNE Therapeutics Inc. (VYNE) on 02 Jul 2021.

Key facts

This page summarizes Matthew T. Wiley's Form 4 filing for VYNE Therapeutics Inc. (VYNE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2021, 16:36.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: -$18,080.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNE transaction

Common Stock

Tax liability

Transaction value: $18,080
Shares: -5,151
Change %: -4.5%
Price: $3.51
Shares after: 109,246
Date: 30 Jun 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.